Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients
- PMID: 33130991
- DOI: 10.1007/s00595-020-02166-5
Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients
Abstract
Purpose: We recently revealed the preoperative lymphocyte C-reactive protein ratio (LCR) to be a new marker for predicting various outcomes in malignancies. The aim of our present study was to clarify the potential utility of the preoperative LCR for predicting the perioperative risk and oncological outcome in esophageal cancer patients.
Methods: We analyzed the preoperative LCR from 153 esophageal cancer patients to clarify its clinical relevance.
Results: The preoperative LCR was significantly decreased in a stage-dependent manner, and a decreased preoperative LCR was significantly associated with the occurrence of postoperative surgical site infection. Esophageal cancer patients with a low LCR showed a poor outcome in both the overall survival and disease-free survival compared with those who had a high LCR. Multivariate analyses showed that a decreased LCR was an independent prognostic factor for both a poor overall survival and disease-free survival. A decreased preoperative LCR was an independent predictive factor for postoperative surgical site infection and significantly correlated with nutritional and inflammatory indicators. In addition, the LCR was useful for identifying esophageal cancer patients likely to have a poor outcome among patients with and without neoadjuvant chemotherapy.
Conclusions: Assessing the preoperative LCR might help physicians identify populations at high risk for perioperative complication and oncological outcomes, and determine individualized perioperative therapeutic strategies.
Keywords: Chemoradiation; Esophageal cancer; Lymphocyte C-reactive protein ratio; Prognosis; Recurrence.
Similar articles
-
Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer.Ann Surg. 2020 Aug;272(2):342-351. doi: 10.1097/SLA.0000000000003239. Ann Surg. 2020. PMID: 32675548
-
Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer.Clin Nutr. 2020 Apr;39(4):1209-1217. doi: 10.1016/j.clnu.2019.05.009. Epub 2019 May 21. Clin Nutr. 2020. PMID: 31155370
-
The clinical impacts of lymphocyte-to-C-reactive protein ratio for esophageal cancer patients who receive curative treatment.J Cancer Res Ther. 2023 Apr-Jun;19(3):556-561. doi: 10.4103/jcrt.jcrt_139_21. J Cancer Res Ther. 2023. PMID: 37470574
-
Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment.In Vivo. 2023 Jan-Feb;37(1):22-35. doi: 10.21873/invivo.13051. In Vivo. 2023. PMID: 36593006 Free PMC article. Review.
-
Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients.Biomed Res Int. 2014;2014:142425. doi: 10.1155/2014/142425. Epub 2014 Apr 27. Biomed Res Int. 2014. PMID: 24877056 Free PMC article. Review.
Cited by
-
Prediction of postoperative complications after hepatectomy with dynamic monitoring of central venous oxygen saturation.BMC Surg. 2023 Nov 14;23(1):343. doi: 10.1186/s12893-023-02238-6. BMC Surg. 2023. PMID: 37957615 Free PMC article.
-
Prognostic role of preoperative lymphocyte/C-reactive protein associated with upper gastrointestinal cancer: a meta-analysis.Front Oncol. 2023 Oct 2;13:1181649. doi: 10.3389/fonc.2023.1181649. eCollection 2023. Front Oncol. 2023. PMID: 37849797 Free PMC article.
-
Prognostic significance of the novel nutrition-inflammation marker of lymphocyte-C-reactive protein ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy.Front Nutr. 2023 Jul 20;10:1162280. doi: 10.3389/fnut.2023.1162280. eCollection 2023. Front Nutr. 2023. PMID: 37545573 Free PMC article.
-
Preoperative Prognostic Nutritional Index Predict Survival in Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction: A Retrospective Study Based on Propensity Score Matching Analyses.Cancer Manag Res. 2023 Jul 5;15:591-599. doi: 10.2147/CMAR.S415618. eCollection 2023. Cancer Manag Res. 2023. PMID: 37431429 Free PMC article.
-
The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.Surg Today. 2023 Aug;53(8):940-948. doi: 10.1007/s00595-022-02638-w. Epub 2023 Jan 3. Surg Today. 2023. PMID: 36595075
References
-
- Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global burden of disease study. JAMA Oncol. 2017;3(4):524–48. - DOI
-
- Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5. Eur J Can. 2015;51(15):2144–57. - DOI
-
- Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nature reviews. Clin Oncol. 2015;12(10):584–96.
-
- Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. - DOI
-
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
